BIOMARIN PHARMACEUTICAL INC
BMRN · Pharmaceutical Preparations · 193.3M shares · +2%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: -$157M (gross $50M, SBC $207M)
Reference price $53.85 · est. market cap ~$10.4B — last insider sale, 2026-05-07 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
B78Rare-disease biotech (Voxzogo/enzyme therapies) — profitable with strong FCF and a cash-rich balance sheet.
Strengths
- Strong free cash flow — FCF $725M (95th), FCF margin 23%
- Profitable, growing — operating margin 13% (84th), revenue +13%
- Cash-rich — current ratio 5.2 (60th)
Risks
- Earnings dip — net income -18%
- Rare-disease-portfolio concentration — per 10-K
- Pipeline-execution dependence — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Strong balance sheetStrong balance sheet — $2.1B cash & investments
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Notable holderHeld by 6 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, FMR LLC +3 more (as of 2026-03-31)
- Revenue declineRevenue -12.4% YoY
- Insider sellingInsider selling — 4 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$3M, last 6mo) Form 4 ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
77.7%
Operating margin
12.7%
Net margin
10.8%
Return on equity
5.7%
Return on assets
4.6%
Revenue growth (QoQ)
-12.4%
Net-income growth
-18.3%
Current ratio
5.2×
Free cash flow
$725M
EBITDA
$489M
Tangible book value
$5.7B
Cash & investments
$2.1B
Stock comp / revenue
5.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-02 | Walbert Timothy P | Grant | 7.5K | — |
| 2026-06-02 | Ho Maykin | Grant | 7.5K | — |
| 2026-06-02 | HOMBACH ROBERT J. | Grant | 7.5K | — |
| 2026-06-02 | Enyedy Mark J | Grant | 7.5K | — |
| 2026-06-02 | Dere Willard H | Grant | 7.5K | — |
| 2026-06-02 | CLARK IAN T | Grant | 7.5K | — |
| 2026-06-02 | Bodem Barbara W. | Grant | 7.5K | — |
| 2026-06-02 | ANDERSON ELIZABETH M | Grant | 7.5K | — |
| 2026-06-02 | Countouriotis Athena | Grant | 7.5K | — |
| 2026-05-20 | Hubbard Cristin | Tax withheld | 2.3K | $50.20 |
| 2026-05-07 | Friberg Gregory R | Sell | 3.3K | $53.85 |
| 2026-03-18 | Davis George Eric | Tax withheld | 1.3K | $56.05 |
| 2026-03-17 | Hardy Alexander | Tax withheld | 4.3K | $56.05 |
| 2026-03-17 | Friberg Gregory R | Tax withheld | 1.6K | $56.05 |
| 2026-03-17 | Hubbard Cristin | Tax withheld | 1.2K | $56.05 |
| 2026-03-17 | Guyer Charles Greg | Tax withheld | 1.7K | $56.05 |
| 2026-03-17 | Mueller Brian | Tax withheld | 2.1K | $56.05 |
| 2026-03-16 | Hubbard Cristin | Grant | 15K | — |
| 2026-03-16 | Friberg Gregory R | Grant | 19K | — |
| 2026-03-16 | Guyer Charles Greg | Grant | 15K | — |
| 2026-03-16 | Davis George Eric | Tax withheld | 7.2K | $58.51 |
| 2026-03-16 | Davis George Eric | Grant | 15K | — |
| 2026-03-16 | Mueller Brian | Grant | 19K | — |
| 2026-03-16 | Hardy Alexander | Grant | 62K | — |
| 2026-03-13 | Guyer Charles Greg | Tax withheld | 9.1K | $58.51 |
| 2026-03-13 | Hardy Alexander | Tax withheld | 2.9K | $58.51 |
| 2026-03-13 | Mueller Brian | Tax withheld | 9.9K | $58.51 |
| 2026-03-11 | Guyer Charles Greg | Sell | 16K | $60.46 |
| 2026-02-26 | Friberg Gregory R | Sell | 6.3K | $60.38 |
| 2026-02-26 | Davis George Eric | Sell | 26K | $61.36 |
| 2026-02-25 | Davis George Eric | Grant | 6.2K | — |
| 2026-02-25 | Guyer Charles Greg | Grant | 6.2K | — |
| 2026-02-25 | Guyer Charles Greg | Grant | 6.7K | — |
| 2026-02-25 | Guyer Charles Greg | Grant | 2.4K | — |
| 2026-02-25 | Davis George Eric | Grant | 6.7K | — |
| 2026-02-25 | Davis George Eric | Grant | 2.4K | — |
| 2026-02-25 | Mueller Brian | Grant | 7.2K | — |
| 2026-02-25 | Mueller Brian | Grant | 2.6K | — |
| 2026-02-25 | Mueller Brian | Grant | 6.7K | — |
| 2026-01-20 | Ramchandani Rashmi Virendra | Grant | 19K | — |
| 2026-01-20 | Ramchandani Rashmi Virendra | Grant | 7.1K | — |
| 2025-12-01 | Hardy Alexander | Tax withheld | 17K | $55.03 |
| 2025-09-30 | Friberg Gregory R | Tax withheld | 3.3K | $54.16 |
| 2025-08-01 | CLARK IAN T | Grant | 7.0K | — |
| 2025-05-20 | Walbert Timothy P | Grant | 6.7K | — |
| 2025-05-20 | MEIER RICHARD A | Grant | 6.7K | — |
| 2025-05-20 | HOMBACH ROBERT J. | Grant | 6.7K | — |
| 2025-05-20 | Ho Maykin | Grant | 6.7K | — |
| 2025-05-20 | Enyedy Mark J | Grant | 6.7K | — |
| 2025-05-20 | Dere Willard H | Grant | 6.7K | — |
| 2025-05-20 | Countouriotis Athena | Grant | 6.7K | — |
| 2025-05-20 | Bodem Barbara W. | Grant | 6.7K | — |
| 2025-05-20 | ANDERSON ELIZABETH M | Grant | 6.7K | — |
| 2025-05-20 | Burkhart Erin | Sell | 1.8K | $59.31 |
| 2025-05-20 | Hubbard Cristin | Tax withheld | 2.2K | $59.93 |
| 2025-05-19 | Burkhart Erin | Tax withheld | 996 | $59.27 |
| 2025-05-02 | Hubbard Cristin | Sell | 273 | $64.92 |
| 2025-04-30 | Hardy Alexander | Grant | 375 | $54.14 |
| 2025-04-30 | Hubbard Cristin | Grant | 273 | $54.14 |
| 2025-03-19 | Burkhart Erin | Sell | 1.3K | $71.52 |
| 2025-03-17 | Davis George Eric | Grant | 13K | — |
| 2025-03-17 | Burkhart Erin | Grant | 6.0K | — |
| 2025-03-17 | Hubbard Cristin | Grant | 13K | — |
| 2025-03-17 | Friberg Gregory R | Grant | 18K | — |
| 2025-03-17 | Guyer Charles Greg | Grant | 13K | — |
| 2025-03-17 | Mueller Brian | Grant | 17K | — |
| 2025-03-17 | Hardy Alexander | Grant | 44K | — |
| 2025-03-14 | Burkhart Erin | Tax withheld | 823 | $69.44 |
| 2025-03-14 | Guyer Charles Greg | Tax withheld | 20K | $69.44 |
| 2025-03-14 | Hardy Alexander | Tax withheld | 2.9K | $69.44 |
| 2025-03-14 | Mueller Brian | Tax withheld | 18K | $69.44 |
| 2025-03-14 | Davis George Eric | Tax withheld | 16K | $69.44 |
| 2025-03-06 | Guyer Charles Greg | Sell | 7.0K | $71.28 |
| 2025-02-28 | Guyer Charles Greg | Tax withheld | 4.3K | $71.16 |
| 2025-02-25 | Mueller Brian | Grant | 9.4K | — |
| 2025-02-25 | Mueller Brian | Grant | 11K | — |
| 2025-02-25 | Mueller Brian | Grant | 9.7K | — |
| 2025-02-25 | Davis George Eric | Grant | 9.4K | — |
| 2025-02-25 | Guyer Charles Greg | Grant | 11K | — |
| 2025-02-25 | Guyer Charles Greg | Grant | 9.7K | — |
| 2025-02-25 | Guyer Charles Greg | Grant | 9.4K | — |
| 2025-02-25 | Davis George Eric | Grant | 11K | — |
| 2025-02-25 | Davis George Eric | Grant | 9.7K | — |
| 2025-02-24 | Burkhart Erin | Sell | 1.3K | $68.38 |
| 2025-02-24 | Walbert Timothy P | Grant | 3.1K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT03864029 ↗ | Retrospective Observational Safety Effectiveness With Kuvan in hpA Tetrahydrobiopterin Deficiency | — | Completed | 2018-03-09 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-04 | Exec/director changeShareholder vote | filing ↗ |
| 2026-05-04 | ResultsExhibits | filing ↗ |
| 2026-04-27 | Material agreementAcquisition/dispositionDebt obligationReg FDExhibits | filing ↗ |
| 2026-04-23 | Other | filing ↗ |
| 2026-03-16 | Other | filing ↗ |
| 2026-02-23 | ResultsExhibits | filing ↗ |
| 2026-02-12 | Material agreementDebt obligationReg FDExhibits | filing ↗ |
| 2026-01-29 | Reg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-04 | 2026-06-02 | 0001628280-26-040812 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001048477-26-000008 ↗ |
| 8-K | 2026-05-04 | 2026-05-04 | 0001048477-26-000006 ↗ |
| 8-K | 2026-04-27 | 2026-04-27 | 0001193125-26-179243 ↗ |
| 8-K | 2026-04-23 | 2026-04-23 | 0001193125-26-173770 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001193125-26-107314 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001048477-26-000004 ↗ |
| 8-K | 2026-02-23 | 2026-02-23 | 0001048477-26-000002 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001193125-26-048736 ↗ |
| 8-K | 2026-01-29 | 2026-01-29 | 0001193125-26-029401 ↗ |
| 8-K | 2026-01-26 | 2026-01-26 | 0001193125-26-021718 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001193125-26-010508 ↗ |